蒲地蓝消炎口服液对小儿手足口病免疫功能及炎性因子的影响
|
摘要
目的:探讨蒲地蓝消炎口服液对小儿手足口病(Hand foot and mouth disease,HFMD)免疫功能及炎性因子的影响。方法:120例HFMD患儿,根据随机数字表法分为两组,每组60例。对照组予以利巴韦林治疗,观察组在对照组的基础上予以蒲地蓝消炎口服液治疗。连续治疗5 d后,比较两组临床疗效、各症状缓解时间、血清细胞因子水平、免疫功能,并记录两组用药安全性。结果:观察组治疗总有效率为95.00%(57/60)明显高于对照组的83.33%(50/60),差异具有统计学意义(P=0.040);观察组与对照组口腔溃疡愈合时间分别为(3.05±1.18)d、(4.16±1.33)d,皮疹消退时间分别为(2.82±1.34)d、(3.68±1.43)d,退热时间分别为(1.56±1.13)d、(2.07±1.20)d,差异具有统计学意义(P<0.05);观察组肿瘤坏死因子-α(Tumornecrosisfactor-α,TNF-α)、白介素-6(Inter-leukin-6,IL-6)、白介素-8(Inter-leukin-8,IL-8)、干扰素-γ(Interferon-γ,IFN-γ)水平均低于对照组,差异具有统计学意义(P<0.05);观察组免疫球蛋白A(Immunoglobin A,IgA)、免疫球蛋白G(Immunoglobin G,IgG)、免疫球蛋白M(Immunoglobin M,IgM)水平均高于对照组,差异具有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P=0.309)。结论:对HFMD患儿采用蒲地蓝消炎口服液治疗安全性较高,能有效改善患儿免疫功能,降低炎性因子水平,提高临床疗效。
Objective:To explore the effects of Pudilan Anti-inflammatory Oral Liquid on the immune function and inflammatory factors in children with hand foot and mouth disease(HFMD). Methods:A total of 120 children with HFMD were selected and randomly divided into two groups according to the random number table,with 60 cases in each group. The control group was given ribavirin for treatment,whereas the observation group was given Pudilan Anti-inflammatory Oral Liquid and Ribavirin. After continuous treatment of 5 days,the clinical efficacy,remission time of each symptom,serum cytokine level and immune function were compared between the two groups,and the safety in the two groups was recorded. Results:The total effective rate of treatment in the observation group was 95.00%(57/60),significantly higher than that in the control group,which was 83.33%(50/60),and the difference was statistically significant(P=0.040). The oral ulcer healing time in the observation group and the control group was respectively(3.05±1.18)d and(4.16±1.33)d and the rash subsided time was respectively(2.82±1.34)d and(3.68±1.43)d. The pyretolysis time was respectively(1.56±1.13)d and(2.07±1.20)d and the difference was statistically significant(P<0.05). The tumor necrosis factor-α(TNF-α), Interleukin-6(IL-6), Interleukin-8(IL-8) and interferon-y(IFN-y) in the observation group were all shown to be lower than the control group,and the difference was statistically significant(P<0.05). The immunoglobin A(IgA),immunoglobulin G(IgG) and immunoglobulin M(IgM) in the observation group were higher than those of the control group and the differences were statistically significant(P<0.05). The incidence of adverse effects in the two groups showed no statistically significant difference(P=0.309). Conclusion: For children with HFMD,Pudilan Anti-inflammatory Oral Liquid has high safety,which can effectively improve their immune function, reduce the levels of inflammatory factors and improve the clinical curative effect.
Objective:To explore the effects of Pudilan Anti-inflammatory Oral Liquid on the immune function and inflammatory factors in children with hand foot and mouth disease(HFMD). Methods:A total of 120 children with HFMD were selected and randomly divided into two groups according to the random number table,with 60 cases in each group. The control group was given ribavirin for treatment,whereas the observation group was given Pudilan Anti-inflammatory Oral Liquid and Ribavirin. After continuous treatment of 5 days,the clinical efficacy,remission time of each symptom,serum cytokine level and immune function were compared between the two groups,and the safety in the two groups was recorded. Results:The total effective rate of treatment in the observation group was 95.00%(57/60),significantly higher than that in the control group,which was 83.33%(50/60),and the difference was statistically significant(P=0.040). The oral ulcer healing time in the observation group and the control group was respectively(3.05±1.18)d and(4.16±1.33)d and the rash subsided time was respectively(2.82±1.34)d and(3.68±1.43)d. The pyretolysis time was respectively(1.56±1.13)d and(2.07±1.20)d and the difference was statistically significant(P<0.05). The tumor necrosis factor-α(TNF-α), Interleukin-6(IL-6), Interleukin-8(IL-8) and interferon-y(IFN-y) in the observation group were all shown to be lower than the control group,and the difference was statistically significant(P<0.05). The immunoglobin A(IgA),immunoglobulin G(IgG) and immunoglobulin M(IgM) in the observation group were higher than those of the control group and the differences were statistically significant(P<0.05). The incidence of adverse effects in the two groups showed no statistically significant difference(P=0.309). Conclusion: For children with HFMD,Pudilan Anti-inflammatory Oral Liquid has high safety,which can effectively improve their immune function, reduce the levels of inflammatory factors and improve the clinical curative effect.
引文
[1] Sinha DP,Raut CG,Jayaprakash H,et al. Molecular diagnosis of enteroviruses associated with hand,foot and mouth disease(HFMD)[J]. Indian J Pediatr,2014,81(11):1242.
[2] Zhen JB,Yi PL,Jie H,et al. The significance of Notch ligand expression in the peripheral blood of children with hand,foot and mouth disease(HFMD)[J]. BMC Infect Dis,2014,14:337.
[3] Lin JN, Lin CL, Lin MC, et al.Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective,population-based,Taiwanese-registry,cohort study[J].Lancet Oncology,2015,16(13):1335-1343.
[4] 刘秋云,李黎辉,张和成.蒲地蓝消炎口服液联合利巴韦林颗粒治疗儿童手足口病38例[J].中国药业,2015,24(22):223-224.
[5] 中华人民共和国卫生部.手足口病诊治指南[S].北京:中华人民共和国卫生部,2010.
[6] 胡亚美,江载芳.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2002:802-810.
[7] 肖贵宝,冯萍,陈立宇.单磷酸阿糖腺苷与利巴韦林治疗手足口病的疗效研究[J].中国感染控制杂志,2017,16(3):263-266.
[8] 初艳慧,刘潇潇,孙小宇,等.重症手足口病例的临床特征和流行病学分析[J].实用预防医学,2014,21(9):1074-1076.
[9] 张志刚,蔡钢.手足口病方辅助治疗手足口病患儿的临床疗效及对细胞因子的影响研究[J].中国全科医学,2016,19(24):2935-2938.
[10] 易天江,谢睿彬,严汝庆,等.七叶皂苷钠治疗2期手足口病的临床研究与应用[J].重庆医学,2016,45(35):5001-5003.
[11] 张志刚,蔡钢.手足口病方辅助治疗手足口病患儿的临床疗效及对细胞因子的影响研究[J].中国全科医学,2016,19(24):2935-2938.
[12] 沈世富.蓝芩口服液联合康复新液治疗小儿手足口病的疗效分析[J].河北医药,2013,5(19):3012-3013.
[13] 陈洁,庄进飞,温正旺,等.甘草泻心汤联合人免疫球蛋白治疗HFMD患儿对hs-CRP及心肌酶谱的影响分析[J].中华中医药学刊,2015,33(11):2795-2797.
[14] 李秀惠,李双杰,温韬,等.热毒宁注射液治疗重型手足口病的临床疗效评价[J].中华中医药杂志,2014,29(2):362-365.
[15] 毛其芬,崔大伟,杨先知,等.手足口病患儿细胞因子水平及免疫球蛋白的变化及其临床意义[J].中国微生态学杂志,2017,29(3):305-308.
[16] 况凡.手足口病患儿淋巴细胞亚群与红细胞锌及超敏C反应蛋白水平分析[J].重庆医学.2016.45(1):69-70.
[17] 臧亚勤,徐亮,沈耀红.蒲地蓝消炎口服液联合重组人干扰素α1b注射液治疗普通型手足口病的疗效观察[J].现代药物与临床,2016,31(12):1967-1970.
[18] 卞丽玲,杨丰文,王媛,等.蒲地蓝消炎口服液治疗小儿化脓性扁桃体炎有效性及安全性的系统评价[J].中国中药杂志,2017,42(8):1482-1488.
[19] 赵润林,张素英,谢琼.蒲地蓝消炎口服液与利巴韦林治疗手足口病的疗效观察[J].中国中医药科技,2014,21(z1):46.
[20] 曹永宁,王永莉.蒲地蓝消炎口服液佐治小儿手足口病临床观察[J].中国中医急症,2014,23(9):1730-1731.
[2] Zhen JB,Yi PL,Jie H,et al. The significance of Notch ligand expression in the peripheral blood of children with hand,foot and mouth disease(HFMD)[J]. BMC Infect Dis,2014,14:337.
[3] Lin JN, Lin CL, Lin MC, et al.Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective,population-based,Taiwanese-registry,cohort study[J].Lancet Oncology,2015,16(13):1335-1343.
[4] 刘秋云,李黎辉,张和成.蒲地蓝消炎口服液联合利巴韦林颗粒治疗儿童手足口病38例[J].中国药业,2015,24(22):223-224.
[5] 中华人民共和国卫生部.手足口病诊治指南[S].北京:中华人民共和国卫生部,2010.
[6] 胡亚美,江载芳.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2002:802-810.
[7] 肖贵宝,冯萍,陈立宇.单磷酸阿糖腺苷与利巴韦林治疗手足口病的疗效研究[J].中国感染控制杂志,2017,16(3):263-266.
[8] 初艳慧,刘潇潇,孙小宇,等.重症手足口病例的临床特征和流行病学分析[J].实用预防医学,2014,21(9):1074-1076.
[9] 张志刚,蔡钢.手足口病方辅助治疗手足口病患儿的临床疗效及对细胞因子的影响研究[J].中国全科医学,2016,19(24):2935-2938.
[10] 易天江,谢睿彬,严汝庆,等.七叶皂苷钠治疗2期手足口病的临床研究与应用[J].重庆医学,2016,45(35):5001-5003.
[11] 张志刚,蔡钢.手足口病方辅助治疗手足口病患儿的临床疗效及对细胞因子的影响研究[J].中国全科医学,2016,19(24):2935-2938.
[12] 沈世富.蓝芩口服液联合康复新液治疗小儿手足口病的疗效分析[J].河北医药,2013,5(19):3012-3013.
[13] 陈洁,庄进飞,温正旺,等.甘草泻心汤联合人免疫球蛋白治疗HFMD患儿对hs-CRP及心肌酶谱的影响分析[J].中华中医药学刊,2015,33(11):2795-2797.
[14] 李秀惠,李双杰,温韬,等.热毒宁注射液治疗重型手足口病的临床疗效评价[J].中华中医药杂志,2014,29(2):362-365.
[15] 毛其芬,崔大伟,杨先知,等.手足口病患儿细胞因子水平及免疫球蛋白的变化及其临床意义[J].中国微生态学杂志,2017,29(3):305-308.
[16] 况凡.手足口病患儿淋巴细胞亚群与红细胞锌及超敏C反应蛋白水平分析[J].重庆医学.2016.45(1):69-70.
[17] 臧亚勤,徐亮,沈耀红.蒲地蓝消炎口服液联合重组人干扰素α1b注射液治疗普通型手足口病的疗效观察[J].现代药物与临床,2016,31(12):1967-1970.
[18] 卞丽玲,杨丰文,王媛,等.蒲地蓝消炎口服液治疗小儿化脓性扁桃体炎有效性及安全性的系统评价[J].中国中药杂志,2017,42(8):1482-1488.
[19] 赵润林,张素英,谢琼.蒲地蓝消炎口服液与利巴韦林治疗手足口病的疗效观察[J].中国中医药科技,2014,21(z1):46.
[20] 曹永宁,王永莉.蒲地蓝消炎口服液佐治小儿手足口病临床观察[J].中国中医急症,2014,23(9):1730-1731.